|
gptkbp:instance_of
|
gptkb:blockade
|
|
gptkbp:approves
|
gptkb:1992
|
|
gptkbp:atccode
|
C07 AB02
|
|
gptkbp:bioavailability
|
approximately 50%
|
|
gptkbp:brand
|
gptkb:Toprol-XL
|
|
gptkbp:casnumber
|
98418-47-4
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C15 H25 NO3
|
|
gptkbp:clinical_trial
|
angina studies
heart failure studies
hypertension studies
post-MI studies
|
|
gptkbp:contraindication
|
gptkb:asthma
heart block
severe bradycardia
|
|
gptkbp:dosage_form
|
extended-release
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
avoid alcohol
do not stop abruptly
monitor heart rate
report any breathing issues
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:formulation
|
sustained-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Toprol-XL
|
|
gptkbp:indication
|
arrhythmias
chronic heart failure
post-myocardial infarction
|
|
gptkbp:ingredients
|
gptkb:metoprolol
|
|
gptkbp:interacts_with
|
gptkb:digoxin
NSAIDs
antidiabetic drugs
calcium channel blockers
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
3 to 7 hours
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:depression
dizziness
fatigue
bradycardia
|
|
gptkbp:strength
|
100 mg
50 mg
200 mg
25 mg
|
|
gptkbp:trade
|
metoprolol succinate
|
|
gptkbp:used_for
|
hypertension
heart failure
angina pectoris
|
|
gptkbp:bfsParent
|
gptkb:metoprolol
|
|
gptkbp:bfsLayer
|
5
|